OHKF Insight Forum New Economy Series Shortage of Medical Professionals Poses Challenges Breakthroughs in Artificial Intelligence Offer Solutions
OHKF Insight Forum New Economy Series Shortage of Medical Professionals Poses Challenges Breakthroughs in Artificial Intelligence Offer Solutions
(23 October 2025, Hong Kong) Our Hong Kong Foundation (OHKF) presented the New Economy Series of the Insight Forum, entitled “Biotech Innovations: From AI to Bio-Agriculture — Hong Kong’s Path Towards a Biotech Hub”. following the same session on October 23. The forum further explored how AI Innovation drive the development of healthcare.
The Forum was honoured to have Ms Simone Song, Founder and Senior Partner of ORI Capital as the speaker. Explore AI Innovation in Healthcare, including 4 sessions (including the 2 sessions on October 23): AI for Disruptive Medicine: Revolutionizing Drug Development, AI for Lifesaving Diagnostics: Faster and Smarter, Next-Gen Medtech – Biomaterials & Micro-robotics and Bio-Agriculture: Lab to Table for Tomorrow’s Plate.
Ms Simone Song said, “Under the continuous advancement in technology, MedTech is a steadily growing industry. Over the past decade, the MedTech industry has experienced consistent revenue growth, with our compound annual growth rate of 5.9%. This steady expansion reflects ongoing advancement in medical technologies and increasing global demand for innovative healthcare solutions. Looking ahead to 2035, this industry is projected to maintain a stable growth trajectory.”
Ms Becky Chan, Approach-specific Scientist of ORI Capital, said, “Looking ahead, AI advancement aims to increase robotic autonomy, enabling robots to assist the surgical decision. And to perform finer and faster operations. This can significantly address the challenge. Like, surgeon shortage and resource constraint. Ultimately, it will improve patient outcome and also the quality of surgical care.”
Mr Eddie Song, Approach-specific Scientist of ORI Capital, said “With global population projected to reach 10 billion by mid-century, protein demand is expected to rise by 52%. If the entire protein supply still relies solely on livestock farming. The ecosystem will inevitably be pushed beyond sustainable threshold. So alternative protein of a viable pathway to satisfy all these demands without animal exploitation or environmental overload.”
Ms Simone Song said on the sessions on October 23, “The traditional drug discovery process faces a 95% failure rate and $60 billion in annual capital waste. Through ORI's proprietary AI platform ‘ORIzon’, which adopts a patient-first philosophy—starting with unmet medical needs to select clinically validated modalities and targets— ‘ORIzon’ optimises target identification, molecule construction, and clinical trials, reducing timelines by 40 to 60%, cutting R&D costs by $54 billion, and boosting success rates by 16.7%.”
The Forum attracted a full house of attendees, including entrepreneurs, C-suite executives and industry pioneers and strong support from a wide range of sectors. Attendees of both this forum and the forum in the same series that held on 23 October were awarded a Certificate of Attendance.
(23 October 2025, Hong Kong) Our Hong Kong Foundation (OHKF) presented the New Economy Series of the Insight Forum, entitled “Biotech Innovations: From AI to Bio-Agriculture — Hong Kong’s Path Towards a Biotech Hub”. following the same session on October 23. The forum further explored how AI Innovation drive the development of healthcare.
The Forum was honoured to have Ms Simone Song, Founder and Senior Partner of ORI Capital as the speaker. Explore AI Innovation in Healthcare, including 4 sessions (including the 2 sessions on October 23): AI for Disruptive Medicine: Revolutionizing Drug Development, AI for Lifesaving Diagnostics: Faster and Smarter, Next-Gen Medtech – Biomaterials & Micro-robotics and Bio-Agriculture: Lab to Table for Tomorrow’s Plate.
Ms Simone Song said, “Under the continuous advancement in technology, MedTech is a steadily growing industry. Over the past decade, the MedTech industry has experienced consistent revenue growth, with our compound annual growth rate of 5.9%. This steady expansion reflects ongoing advancement in medical technologies and increasing global demand for innovative healthcare solutions. Looking ahead to 2035, this industry is projected to maintain a stable growth trajectory.”
Ms Becky Chan, Approach-specific Scientist of ORI Capital, said, “Looking ahead, AI advancement aims to increase robotic autonomy, enabling robots to assist the surgical decision. And to perform finer and faster operations. This can significantly address the challenge. Like, surgeon shortage and resource constraint. Ultimately, it will improve patient outcome and also the quality of surgical care.”
Mr Eddie Song, Approach-specific Scientist of ORI Capital, said “With global population projected to reach 10 billion by mid-century, protein demand is expected to rise by 52%. If the entire protein supply still relies solely on livestock farming. The ecosystem will inevitably be pushed beyond sustainable threshold. So alternative protein of a viable pathway to satisfy all these demands without animal exploitation or environmental overload.”
Ms Simone Song said on the sessions on October 23, “The traditional drug discovery process faces a 95% failure rate and $60 billion in annual capital waste. Through ORI's proprietary AI platform ‘ORIzon’, which adopts a patient-first philosophy—starting with unmet medical needs to select clinically validated modalities and targets— ‘ORIzon’ optimises target identification, molecule construction, and clinical trials, reducing timelines by 40 to 60%, cutting R&D costs by $54 billion, and boosting success rates by 16.7%.”
The Forum attracted a full house of attendees, including entrepreneurs, C-suite executives and industry pioneers and strong support from a wide range of sectors. Attendees of both this forum and the forum in the same series that held on 23 October were awarded a Certificate of Attendance.
